Reuters logo
BRIEF-Knight Therapeutics announces exclusive license agreement with AstraZeneca
2016年12月15日 / 下午12点41分 / 9 个月前

BRIEF-Knight Therapeutics announces exclusive license agreement with AstraZeneca

Dec 15 (Reuters) - Knight Therapeutics Inc

* The financial terms of agreement were not disclosed

* Knight therapeutics- as per agreement, co will be responsible for all commercial, regulatory, certain supply chain activities for movantik in canada, israel

* Movantik is currently under regulatory review in israel and, when approved, will be marketed under name moventig

* Press release - knight therapeutics announces exclusive license agreement with astrazeneca for movantik/moventig(r) in canada and israel Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below